Silver Book Fact

In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.

Katz N, Borenstein D, Birbara C, et al. Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain. Pain. 2011; 152(10): 2248-58. http://www.painjournalonline.com/article/S0304-3959%2811%2900316-2/abstract

Reference

Title
Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain
Publication
Pain
Publication Date
2011
Authors
Katz N, Borenstein D, Birbara C, et al
Volume & Issue
Volume 152, Issue 10
Pages
2248-58
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A proteasome inhibitor was found to reduce pain and joint destruction in an animal model of osteoarthritis, suggesting that nontoxic proteasome inhibitors could offer a novel pharmacotherapy option.  
  • Researchers have developed several sub-types of ion channels that allow inflammation and growth factors to trigger persistent pain.  
  • Subthalamic nuclei deep brain stimulation (STN-DBS) raises pain thresholds in Parkinson’s disease patients.  
  • Pain education programs and pain consultations have been found to improve pain (average pain was 31% versus 20%) and daily interference (20% versus 2.5%) in oncology outpatients. Patient adherence…  
  • Brain imaging is showing that pain changes the structure and function of brain regions that perceive pain, making it persistent. These brain networks and receptor targets are being identified…